May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
January 2021 in “Our Dermatology Online” Oral tofacitinib successfully treated total body hair loss in one patient.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
21 citations
,
April 2025 in “MedComm” Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.
20 citations
,
June 2021 in “British Journal of Dermatology” Use antimalarials like hydroxychloroquine for cutaneous lupus, avoid herbal supplements, and focus on lifestyle changes like sun protection.
9 citations
,
April 2024 in “Metabolites” Cannabis has anti-inflammatory and antimicrobial properties, but more research is needed on its effects on plant and aquatic animal pathogens.
5 citations
,
December 2022 in “Genes” Genetic differences affect how people respond to COVID-19.
2 citations
,
October 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” AIRE deficiency causes hair loss similar to alopecia areata in mice.
1 citations
,
October 2025 in “Journal of Microbiology and Biotechnology” Natural extracts may promote hair growth with fewer side effects than conventional treatments.
January 2026 in “Immunological Reviews” Females generally have stronger immune responses than males due to the X chromosome.
January 2026 in “Experimental Dermatology” Keratinocytes contribute to hidradenitis suppurativa by causing inflammation and worsening the condition.
October 2025 in “Pharmaceutics” Microneedles improve drug delivery for skin diseases, enhancing treatment effectiveness and patient compliance.
December 2022 in “Dermatology and Therapy” Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
60 citations
,
November 2023 in “Biology” Aging skin causes inflammation that affects the whole body.
2 citations
,
November 2019 in “International Journal of Dermatology and Venereology” Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
1 citations
,
May 2025 in “The Journal of Dermatology” Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.
July 2025 in “Journal of the Dermatology Nurses’ Association” Stress affects skin health, and mental health support is crucial for patients with skin conditions.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.